Ra Pharmctl Inc (NASDAQ:RARX) – Jefferies Group issued their Q1 2018 earnings estimates for shares of Ra Pharmctl in a report released on Thursday. Jefferies Group analyst E. Yang expects that the company will post earnings per share of ($0.77) for the quarter. Jefferies Group has a “Buy” rating and a $25.00 price target on the stock. Jefferies Group also issued estimates for Ra Pharmctl’s Q2 2018 earnings at ($0.91) EPS, Q3 2018 earnings at ($0.93) EPS and Q4 2018 earnings at ($1.14) EPS.

A number of other research analysts have also issued reports on RARX. Zacks Investment Research lowered shares of Ra Pharmctl from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Royal Bank Of Canada began coverage on shares of Ra Pharmctl in a report on Thursday, September 14th. They issued an “outperform” rating and a $21.00 price objective for the company. Finally, Credit Suisse Group raised their price target on shares of Ra Pharmctl from $19.00 to $23.00 and gave the stock an “outperform” rating in a report on Friday, November 10th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Ra Pharmctl presently has a consensus rating of “Buy” and an average target price of $24.67.

TRADEMARK VIOLATION WARNING: This story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/11/15/q1-2018-earnings-forecast-for-ra-pharmctl-inc-rarx-issued-by-jefferies-group.html.

Shares of Ra Pharmctl (NASDAQ:RARX) traded down $0.10 during midday trading on Monday, reaching $14.01. 76,600 shares of the company were exchanged, compared to its average volume of 118,566. Ra Pharmctl has a 1-year low of $11.20 and a 1-year high of $27.84.

Ra Pharmctl (NASDAQ:RARX) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.06).

Several large investors have recently added to or reduced their stakes in RARX. American International Group Inc. bought a new stake in shares of Ra Pharmctl in the 1st quarter valued at $102,000. TIAA CREF Investment Management LLC increased its stake in shares of Ra Pharmctl by 97.0% in the 1st quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock valued at $167,000 after acquiring an additional 3,859 shares in the last quarter. Alliancebernstein L.P. bought a new stake in shares of Ra Pharmctl in the 2nd quarter valued at $195,000. Wells Fargo & Company MN increased its stake in shares of Ra Pharmctl by 151.8% in the 1st quarter. Wells Fargo & Company MN now owns 9,455 shares of the company’s stock valued at $202,000 after acquiring an additional 5,700 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Ra Pharmctl by 30.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock valued at $204,000 after acquiring an additional 2,543 shares in the last quarter. Institutional investors own 66.74% of the company’s stock.

About Ra Pharmctl

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Earnings History and Estimates for Ra Pharmctl (NASDAQ:RARX)

Receive News & Stock Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related stocks with our FREE daily email newsletter.